Various in vitro studies were performed to evaluate their therapeutic efficacy over native drug and non-conjugated NPs in HER2+ SKBR3 breast cancer cell line (Parhi and Sahoo 2015). The gene discussed is ERBB2; the disease is breast carcinoma.